.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Nanotechnology in oncology represents a transformative shift in modern cancer care. Traditional therapies frequently encounter significant limitations such as poor tumor selectivity and systemic toxicity. However, advanced nanoparticle-based strategies provide a promising solution. These platforms improve drug solubility and extend circulation time within the body. Consequently, they allow for more effective drug delivery directly to the malignant site.
Researchers utilize both passive and active mechanisms for tumor targeting. For instance, the enhanced permeability and retention (EPR) effect facilitates passive accumulation. Furthermore, active targeting employs specific ligands to bind to cancer cell receptors. This strategy enhances intracellular uptake significantly. Moreover, these approaches minimize the impact on healthy tissues. Therefore, patients often experience fewer side effects compared to traditional chemotherapy.
Despite immense preclinical potential, clinical translation remains difficult. Factors like patient-specific heterogeneity and regulatory hurdles contribute to high attrition rates. Additionally, some approved nanomedicines like Doxil and Abraxane have set a high standard. However, newer formulations sometimes fail to show consistent clinical benefits. Consequently, the medical community must focus on standardizing toxicological protocols and manufacturing processes. Ultimately, this integration aims to refine precision cancer therapy for better patient outcomes.
The enhanced permeability and retention (EPR) effect refers to the tendency of nanoparticles to accumulate in tumor tissue more than in normal tissues. This happens because tumor vessels are often leaky, and the lymphatic drainage is typically impaired. Consequently, this passive mechanism allows for higher drug concentrations at the cancer site.
Several nanomedicines have achieved clinical success. Specifically, liposomal doxorubicin (Doxil) and albumin-bound paclitaxel (Abraxane) are widely used. Furthermore, these formulations help reduce the severe side effects associated with their traditional, non-nanoparticle counterparts.
The main barriers include the significant variability in tumor types and patient-specific responses. Additionally, long-term toxicity concerns and complex manufacturing requirements often slow down the regulatory process. Therefore, bridging the gap between lab research and clinical practice requires more standardized protocols.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.
References
Fahim YA et al. Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment. Discov Nano. 2026 Jun 10. doi: undefined. PMID: 42268351.
Shi J et al. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2023.
Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2021.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Nanotechnology in oncology offers transformative drug delivery systems to improve selectivity and reduce toxicity. While preclinical results are strong, clinical translation faces hurdles like patient heterogeneity and regulatory barriers. This review explores synthesis methods and the future of precision therapy.
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
